Rigel Pharmaceuticals develops therapies for patients with hematologic disorders and cancer. Products include Tavalisse, Rezlidhia, and GAVRETO. Rezlidhia treats relapsed or refractory AML with IDH1 mutation. GAVRETO treats metastatic RET fusion-positive lung and thyroid cancers. The company also develops R289, an oral IRAK1/4 Inhibitor, in Phase 1b trials.
| Indicator | Value |
|---|---|
| PER | 22.2 |
| EV/EBITDA | 13.7 |
| Price/Free Cash Flow' | 12.5 |
| ROIC | 49.8% |
| Net Debt/EBITDA | 0.1 |